

Abstract 3313 Phase 1 Study of CARTddBCMA for the Treatment of Subjects with Relapsed and/or Refractory Multiple Myeloma

Matthew Frigault, MD, MS¹, Jacalyn Rosenblatt, MD², Binod Dhakal, MBBS³, Noopur Raje, MD⁴, Daniella Cook, BS^{5*}, Mahmoud R. Gaballa, MD⁶, Estelle Emmanuel-Alejandro^{7*}, Danielle Nissen^{8*}, Christine Cornwell^{9*}, Kamalika Banerjee^{9*}, Anand Rotte, PhD^{9*}, Christopher R. Heery, MD⁹, David Avigan, MD¹⁰, Andrzej Jakubowiak, MD, PhD¹¹ and Michael R. Bishop, MD¹²

.....

Background and Methods

CART-ddBCMA is an autologous CAR-T containing a novel synthetic protein^{1,2} binding domain (non-scFv) engineered to reduce the risk of immunogenicity and is highly stable

Phase 1 first-in-human trial has completed enrollment of relapsed and/or refractory myeloma


- Prior IMiD, PI, and CD38-targeted therapy required
- Received ≥3 prior therapies or triple refractory

2 Dose Levels evaluated, 6 subjects in each dose escalation cohort

 DL1 = 100 x 10⁶ CAR+ cells; DL2 = 300 x 10⁶ CAR+ cells

Expansion cohort is enrolled at DL1


¹Rotte, et al. "BCMA targeting CAR T cells using a novel D-domain binder for multiple myeloma: clinical development update." *Immuno-Oncology Insights 2022; 3(1), 13–24* ²Frigauli et al. "Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory Multiple Myeloma." Blood Advances 2022; bloodadvances.2022007210. doi: https://doi.org/10.1182/bloodadvances.2022007210.




¹ Chan, KF. et al. 2018.,Nat Commun 9:1026-1026

² Bjerragaard-Anderson, K., et al 2018. Sci. Rep., 8:10836-10836.

³ https://commons.wikimedia.org/wiki/File:113V_(Lama_VHH_domain_unligated).png#file



Patient Disposition



Patient Demographics (as of 31 Oct 2022)

Characteristics	Dose Level 1 100 million CAR-T (n=32)	Dose Level 2 300 million CAR-T (n=6)	Total (n=38)
Age, median (min - max)	66 (44 - 76)	60 (52 - 65)	66(44 - 76)
Gender	18 Male (56%) 14 Female (44%)	5 Male (83%) 1 Female (17%)	23 Male (61%) 15 Female (39%)
ECOG PS*			
0 1	9/32 (28%) 23/32 (72%)	3/6 (50%) 3/6 (50%)	12/38(32%) 26/38 (68%)
High Risk Prognostic Feature	16/32 (50%)	6/6 (100%)	22/38 (58%)
BMPC ≥60%	6/32 (19%)	3/6 (50%)	9/38 (24%)
ISS Stage III (B2M ≥ 5.5)	3/32 (9%)	2/6 (33%)	5/38 (13%)
Extra-medullary disease	10/32 (31%)	3/6 (50%)	13/38 (34%)
High Risk Cytogenetics**	9/32 (28%)	2/6 (33%)	11/38 (29%)
Prior Lines of Therapy, Median (min - max)	5 (3 - 7)	4 (3 - 16)	4 (3 - 16)
Triple refractory***	32/32 (100%)	6/6 (100%)	38/38 (100%)
Penta refractory	21/32 (66%)	5/6 (83%)	26/38 (68%)
lgG myeloma	19	5	24
lgA myeloma	6	0	6
Light chain only	5	1	6


*Eastern Cooperative Oncology Group Performance Status Scale **Defined as Del 17p, t(14;16), t(4;14).

***Note: modified from ASCO 2022 due to data cleaning efforts.

CART-ddBCMA Manufacturability: Reliable Process, Consistent Product


100% of initiated cell product runs released to date

Cell Viability ~



CAR Positivity (+)


S




Low inter-patient variability in CAR⁺ cells: median 70%

2022

Vector Copy Number




Low inter-patient variability in CAR expression/cell: median 2.2 copies/cell



Total Manufactured Cells

High yield: ≥3 doses of DL1 can be administered from a single manufacture run

Potential for Best-in-Class Treatment



*Patient initiated subsequent therapy prior to official PD. **Subject 30 died of cardiac arrest secondary to drug overdose.

MRD abbreviations: NE = not evaluable, failed calibration; POS = positive; Pending = sample being analyzed


022

N

Presentation

Corporate

CART-ddBCMA Responses Deepen Over Time



CR/SCR VGPR PR


Minimum months since infusion (M)	1	6	12	18
Sample Size (n)*	38	35	25	16
Median Follow-up (mo)	15.0	16.4	18.9	22.9
High Risk Features** # (%)	22 (58%)	21 (60%)	19 (76%)	13 (81%)
ORR	100%	100%	100%	100%
CR/sCR rate***	27 (71%)	25(71%)	20 (80%)	13 (81%)

*Includes patients who were dosed at least M months prior or have had follow visit at Mth-month as of 11/22/22.

**High risk features defined as presence of EMD, BMPC ≥ 60, or B2M ≥ 5.5

***Calculated using number of patients who reached CR/sCR divided by number treated at least 1, 6, 12, or 18 months prior

Responses in Subgroups



	Patients n	6-month PFS %	12-month PFS %	18-month PFS %
	(%)	(95% сı)	(95% сı)	(95% cl)
Overall	38	91.8%	72.7%	64.6%
	(100%)	(76.7%, 97.2%)	(52.2%, 85.5%)	(43.7%, 79.4%)
≥ 65 years	20	95.0%	82.3%	75.4%
	(52.6%)	(69.4%, 99.3%)	(54.3%, 94.0%)	(46.7%, 90.1%)
Complete Responders	27	96.2%	86.0%	80.7%
	(71.1%)	(75.7%, 99.4%)	(62.3%, 95.3%)	(55.9%, 92.4%)
High Risk Features*	22	90.5%	69.2%	63.4%
	(57.9%)	(67.0%, 97.5%)	(43.7%, 84.9%)	(38.0%, 80.7%)
Extramedullary disease	13	91.7%	64.2%	64.2%
	(34.2%)	(53.9%, 98.8%)	(30.2%, 84.8%)	(30.2%, 84.8%)
High Risk Cytogenetics	11	80.8%	69.2%	69.2%
	(28.9%)	(42.3%, 94.8%)	(31.1%, 89.1%)	(31.1%, 89.1%)

CART-ddBCMA: 100% ORR, High CR Rate, and Durable Responses Demonstrate Potential for Best-in-Class Treatment

	CART-ddBCMA		LEGEND-2	CARTI	TUDE-1
Minimum follow-up (mo.)	1	18	1	1.5	13.5 (est.)
Sample Size (n)	38	16	57	97	
Median Follow-up (mo.)	15.0	22.9	8	12.4	24
EMD %	34%	50%	30%	13%	13%
ORR	100%	100%	88%	97%	98%
CR rate	71%	81%	68%	67%	83%
Kaplan Meier Estimate PFS Rate	All subjects		LEGEND-2 All subjects	CARTITUDE-1 All subjects	
@ 6 months	91.8% (76.7%, 97.2%)		~82%	87%	
@ 12 months	72.7% (52.2%, 85.5%)		~70%	~75%	
@18 months	64.6% (43.7%, 79.4%)		~41%	~67%	

Based on preliminary data cut October 31, 2022

LEGEND-2 estimates are based on KM curves from Zhao BMC 2018 (Figure 2a) and CARTITUDE-1 estimates are based on KM curves from Martin JCO 2022 (Fig 2a).



Adverse Event Profile (as of 31 Oct 2022)

Grade 3/4 AEs (non-CRS/ICANS) ≥5% after cell infusion (N=38)		CAR-T-associated AEs Per ASTCT criteria	100 million (N=32)		300 million (N=6)		
Hematologic		Cytokine Release	Grade 1/2	Grade 3	Grade 1/2	Grade 3	
Neutrophil count decreased	29 (76.3%)	Syndrome (CRS)	30 (94%)	0	5 (83%)	1 (17%)	
Anemia	22 (57.9%)						
Thrombocytopenia	15 (39.4%)	Median onset (min-max)* 2 days (1-12 days)		2 day (1-2 days)			
Lymphocyte count decreased	13 (36.8%)	Median duration (min-max)	8 days (2-14 days)		5 days (3-10 days)		
White blood cell count decreased	7 (18.4%)		Grade 1/2	Grade 3	Grade 1/2	Grade 3	
Febrile Neutropenia	6 (15.8%)	Neurotoxicity (ICANs)	5 (16%)	1 (3%)	0	1 (17%)	
Non-hematologic	Non-hematologic		4.5 days (3-6 days)		7 dc	7 days	
Hypertension	3 (7.9%)	Median duration (min-max)	7.5 days (4 - 11 days)		23 days		
Hyponatremia	2 (5.3%)	Toxicity Management				-	
Pain in extremity	2 (5.3%)						
Cellulitis	2 (5.3%)	Tocilizumab 2		27 (84%)		5 (83%)	
Sepsis	2 (5.3%)	Dexamethasone	20 (63%)		2 (33%)		


*Infusion Day 0 is considered Study Day 1

CART-ddBCMA Phase 1: Conclusions

CART-ddBCMA utilizes a novel, synthetic highly stable binding domain

• 2 dose levels studied (100 and 300 million CAR+ T-cells); MTD not reached

Consistency in manufacturing (100% success) highlighted by high CAR-T cell viability, low • inter-patient variability in CAR+ cells and high CAR-T cell yield



100%	Deep and durable responses						
ORR	 All Patients: <u>38/38 (100%) ORR; 27/38 (71%) CR/sCR</u>, 7/38 (18%) VGPR, 4/38 (11%) PR; ≥VGPR = 34/38 (89%) 						
per IMWG	• Pts w/ 12 mo f/u: 25/25 (100%) ORR; 20/25 (80%) CR/sCR, 3/25 (12%) VGPR, 2/25 (8%) PR; ≥VGPR = 23/25 (92%)						
across both dose levels • Pts w/ 18 mo f/u: <u>16/16 (100%) ORR; 13/16 (81%) CR/sCR</u> , 1/16 (6%) VGPR, 2/16 (13%) PR; ≥VGPR = 14/16 (88%)							
Median Duration of Response Not Reached for Overall PopulationDurable responses in patients with high-risk features• PFS Rate: @6 months 92%, @12 months 73%, @ 18 months 65%• PFS rate 63% @18 months in population 		24 of 27 (89%) of MRD evaluable subjects achieved Negativity at ≥10 ⁻⁵					
No tissue-tarNo cases grad	t Profile appears potent geted toxicities observed de 3 (or greater) CRS, 1 cas eurotoxicity or parkinsonia 1=38)	Pivotal Phase 2 Trial is now enrolling! (RP2D, 115±10 million CAR+ T cells)					